bioRxiv preprint doi: https://doi.org/10.1101/001321; this version posted July 26, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Role of GSK-3 in mammary gland tumorigenesis (Revised) Dembowy et al. Effect of glycogen synthase kinase-3 inactivation on mouse mammary gland development and oncogenesis Joanna Dembowy1,2, Hibret A. Adissu3,4, Jeff C. Liu5, Eldad Zacksenhaus2, 4, 5 and James R. 1,2 Woodgett 1. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada 2. Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada 3. Pathology Core, Centre for Modelling Human Disease, Toronto Centre for Phenogenomics, Toronto, Ontario, Canada 4. Toronto General Hospital Research Institute, Toronto, Ontario, Canada 5. Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada Address correspondence to: James Woodgett, Mount Sinai Hospital, Room 982, 600 University Avenue, Toronto, Ontario, Canada M5G 1X5, Tel: 416-586-8811,
[email protected] We declare no conflict of interest. Running title: Role of GSK-3 in mammary gland tumorigenesis bioRxiv preprint doi: https://doi.org/10.1101/001321; this version posted July 26, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Many components of Wnt/β-catenin signaling pathway have critical functions in mammary gland development and tumor formation, yet the contribution of glycogen synthase kinase-3 (GSK-3α and GSK-3β) to mammopoiesis and oncogenesis is unclear.